OncoSec Medical Incorporated and Duke University School of Medicine announced that they have entered into a collaborative research agreement to evaluate the use of OncoSec’s proprietary Tavoplus (enhanced IL-12 DNA-plasmid) in combination or sequence with a HER2-plasmid vaccine administered with OncoSec’s novel intratumoral delivery system.
CMI/Compas, media buying and planning for the nation’s top healthcare companies and part of WPP, announced the promotion of James Woodland to Chief Strategy and Financial Officer.
Novartis announced that the U.S. Food and Drug Administration accepted the company’s Biologics License Application for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration.
Results from NASA’s landmark Twins Study reveals some interesting, surprising and reassuring data.
The Janssen Pharmaceutical Companies of Johnson & Johnson unveiled new 48-week data for Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg D/C/F/TAF) showing that a high proportion of HIV patients achieved an undetectable viral load through 48 weeks after rapidly starting Symtuza.
Outcome Health, a healthcare innovation company focused on making the point of care experience more meaningful for patients and physicians, announced a new content strategy across its nationwide platform.
CMI/Compas, media planning and buying for the nation’s top healthcare companies and part of WPP, announced the promotion of John Donovan to President of Compas.
Amgen and UCB announced that the U.S. FDA approved Evenity (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
CMI/Compas, media buying and planning for the nation’s top healthcare companies and part of WPP (NYSE:WPP), announces the promotion of Dr. Susan Dorfman to President, CMI. Dorfman was most recently Chief Commercial Officer for CMI/Compas. As President, she is responsible for the growth and future direction of CMI Media, with a strategic focus on integrated […]
NEW YORK, March 22, 2019 /PRNewswire/ — A leading quality rating for the nation’s hospitals appears not to adequately account for the risks of undergoing certain procedures at certain hospitals, particularly joint replacement surgery, according to a new study by researchers at Hospital for Special Surgery (HSS) in New York City. The study, reported in the […]
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!
